Insider Cluster (2 insiders) ·Filed Jun 2, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago
Insider cluster: 2 insiders, $644K total
Actionable Insight • Neutral

The sales are routine post-exercise liquidity events at trivial scale. No bearish read-through. Monitor for any material insider buying (which would be a stronger signal) or for upcoming earnings/catalyst news that could shift sentiment.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
MIRM ▲ +8.62% at T+60d
NEUTRAL call ✓ call won +8.62% · α vs SPY +6.12% · entry $91.84 → $99.75
Entry anchored
Jun 2, 2026
via day open
T+1d
+0.71%
call +0.71% · α +0.31%
$92.49
settled 4mo ago
T+5d
+2.36%
call +2.36% · α +6.18%
$94.00
settled 4mo ago
T+20d
+36.76%
call +36.76% · α +37.76%
$125.59
settled 3mo ago
T+60d
+8.62%
call +8.62% · α +6.12%
$99.75
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Mirum Pharmaceuticals CEO Christopher Peetz and Director Saira Ramasastry sold a combined $644K in open-market sales on June 1, 2026, following a cluster of non-cash derivative exercises by multiple directors on May 29. The sales represent ~0.01% of MIRM's $5.9B market cap — trivial in proportion — and are likely liquidity-driven after option exercises, not a bearish signal. The stock has strong analyst support (95% bullish) and the cluster lacks material dollar weight.

Key Financial Metrics

Direction
selling
Total Value
$644.0K
Insiders
2

Key Facts

  • CEO Peetz sold 2,602 shares at $94.64 for $246K on June 1, 2026
  • Director Ramasastry sold 3,977 shares at $100 for $398K on June 1, 2026
  • Both sales followed non-cash derivative exercises on May 29 (directors) and June 1 (CEO)
  • Total open-market sales of $644K represent ~0.01% of MIRM's $5.9B market cap
  • Analyst consensus is 95% bullish (18 Buy, 1 Hold, 0 Sell)
  • No open-market purchases in the cluster

Financial Impact

Total insider sales of $644K — immaterial relative to $5.9B market cap

insider ownershipdilution

Risk Factors

  • Insider sales could accelerate if stock continues to appreciate, but no evidence of coordinated selling
  • No purchases in cluster — lack of bullish insider signal

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MIRM-1780444246058
16 reports for MIRM
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +28.29%Jun 11, 2026
Filters
Rows
Reports for MIRM — sortable, filterable
TypeNow
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 3/10
$102.24 $98.82▼ −3.35%▼ −1.39%$82.58 (−19.23%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$98.97 $100.61▲ +1.66%▲ +3.55%$82.58 (−16.56%)
Aug 11, 2026
7w ago
Insider Cluster
BEARISH ★ 5/10
$98.97 $100.61▼ −1.66%▼ −3.55%$82.58 (+16.56%)
Aug 10, 2026
7w ago
144
NEUTRAL ★ 3/10
$98.23 $98.30▲ +0.07%▲ +1.13%$82.58 (−15.93%)
Aug 5, 2026
8w ago
8-K
MIXED ★ 6/10
$94.12 $100.63▲ +6.92%▲ +6.32%$82.58 (−12.26%)
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$128.57 $105.79▼ −17.72%▼ −20.99%$82.58 (−35.77%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$99.54 $127.70▲ +28.29%▲ +26.40%$82.58 (−17.04%)
Jun 10, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$94.00 $127.70▲ +35.85%▲ +32.23%$82.58 (−12.15%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$91.84 $125.59▲ +36.76%▲ +37.76%$82.58 (−10.08%)
Jun 1, 2026
17w ago
144
NEUTRAL ★ 3/10
$92.17 $120.46▲ +30.69%▲ +32.26%$82.58 (−10.40%)
Showing 10 of 16

US Market Status

Market Open — Closes in 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 2, 2026